Extranodal NK/T-Cell Lymphoma, Nasal Type · line 1 · SMILE (Steroid + MTX + Ifosfamide + L-asparaginase + Etoposide), 2-4 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-SMILE`

ID	`IND-NK-T-NASAL-1L-SMILE`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-NK-T-NASAL`
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB. Дуже rare у Caucasian populations. Localized + RT — найкращий prognosis. Pembrolizumab для R/R disseminated — окрема Indication.

Used By

Algorithms

ALGO-NK-T-NASAL-1L - ALGO-NK-T-NASAL-1L